HMPL-523 – Patient Worthy

source: pixabay.com

HMPL-523 Earns Breakthrough Therapy Designation in China for ITP

Post author:Jessica Lynn
Post published:February 23, 2022
Post category:Immune thrombocytopenia Immune Thrombocytopenic Purpura

In a recent news release, commercial-stage biopharmaceutical company HUTCHMED shared that its investigational therapy HMPL-523 had received Breakthrough Therapy designation from the National Medical Products Administration (NMPA) in China. HMPL-523…

We believe rare disease patients are people, not a diagnosis. Through education, awareness and some humor, we help patients, caregivers and support persons by providing relevant and often inspirational news and stories.

Our goals are to share stories, cultivate strong community, provide the latest medical findings, connect people and pioneer production of patient worthy information. Help us attain these goals by telling us a little bit about yourself!

Let’s Work Together!

Keep Up to Date

Learn More